Influence of Indomethacin Amphoteric Gel on Gastric Ulcerogenicity and Absorption of Indomethacin in Rats
Identifieur interne : 001490 ( Main/Exploration ); précédent : 001489; suivant : 001491Influence of Indomethacin Amphoteric Gel on Gastric Ulcerogenicity and Absorption of Indomethacin in Rats
Auteurs : Gary G. Liversidge [États-Unis] ; John Dent [États-Unis] ; W. Mark Eickhoff [États-Unis]Source :
- Pharmaceutical Research [ 0724-8741 ] ; 1989-01-01.
English descriptors
Abstract
Abstract: Indomethacin is a potent and efficacious antiinflammatory agent. However, a limiting side effect is its ability to cause gastric ulceration. This study was designed to investigate the effects of an amphoteric gel on the gastric ulcerogenicity and pharmacokinetics of indomethacin. Oral administration (5 mg/kg) in a suspension and a gel formulation were compared to an intravenous (iv) formulation of indomethacin in rats. The iv formulation administered to rats produced large severe ulcers in some rats but not in others. In contrast, the oral suspension produced small ulcers in all rats. The difference in toxicities is attributed to a centrally mediated action as a result of high plasma levels of indomethacin following iv administration, compared to locally mediated action with the suspension, resulting from local high concentrations of indomethacin on the apical epithelial surface because of the presence of indomethacin crystals. Oral administration of the gel formulation did not result in any gastric ulceration and improved the bioavailability of indomethacin to 115.5%, compared with 68.2% for the suspension. The reduced gastrointestinal toxicity of indomethacin in the gel was attributed to the gel's ability to dissolve indomethacin, preventing the localized high concentration observed with the suspension and possibly providing a gastric protectant phospholipid. The gel formulation doubled the oral bioavailability and the t max of indomethacin compared to the suspension but did not affect the half-life. The results indicate that the local irritant effect of indomethacin, in rats, can be reduced by appropriate formulation design and suggest that the ulcerogenicity index for indomethacin can be improved by the use of an amphoteric gel formulation.
Url:
DOI: 10.1023/A:1015895501832
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000379
- to stream Istex, to step Curation: 000359
- to stream Istex, to step Checkpoint: 000634
- to stream Main, to step Merge: 001511
- to stream Main, to step Curation: 001490
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Influence of Indomethacin Amphoteric Gel on Gastric Ulcerogenicity and Absorption of Indomethacin in Rats</title><author><name sortKey="Liversidge, Gary G" sort="Liversidge, Gary G" uniqKey="Liversidge G" first="Gary G." last="Liversidge">Gary G. Liversidge</name></author><author><name sortKey="Dent, John" sort="Dent, John" uniqKey="Dent J" first="John" last="Dent">John Dent</name></author><author><name sortKey="Eickhoff, W Mark" sort="Eickhoff, W Mark" uniqKey="Eickhoff W" first="W. Mark" last="Eickhoff">W. Mark Eickhoff</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:17CAD7BA1E1699BF00CF1177D9CB10112F82CC38</idno><date when="1989" year="1989">1989</date><idno type="doi">10.1023/A:1015895501832</idno><idno type="url">https://api.istex.fr/ark:/67375/1BB-BRLQ6BW8-1/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000379</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000379</idno><idno type="wicri:Area/Istex/Curation">000359</idno><idno type="wicri:Area/Istex/Checkpoint">000634</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000634</idno><idno type="wicri:doubleKey">0724-8741:1989:Liversidge G:influence:of:indomethacin</idno><idno type="wicri:Area/Main/Merge">001511</idno><idno type="wicri:Area/Main/Curation">001490</idno><idno type="wicri:Area/Main/Exploration">001490</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Influence of Indomethacin Amphoteric Gel on Gastric Ulcerogenicity and Absorption of Indomethacin in Rats</title><author><name sortKey="Liversidge, Gary G" sort="Liversidge, Gary G" uniqKey="Liversidge G" first="Gary G." last="Liversidge">Gary G. Liversidge</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Department of Drug Delivery, Smith Kline & French Labs, R&D, P.O. Box 1539, 19406-0939, King of Prussia</wicri:cityArea></affiliation></author><author><name sortKey="Dent, John" sort="Dent, John" uniqKey="Dent J" first="John" last="Dent">John Dent</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Department of Drug Delivery, Smith Kline & French Labs, R&D, P.O. Box 1539, 19406-0939, King of Prussia</wicri:cityArea></affiliation></author><author><name sortKey="Eickhoff, W Mark" sort="Eickhoff, W Mark" uniqKey="Eickhoff W" first="W. Mark" last="Eickhoff">W. Mark Eickhoff</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Department of Drug Delivery, Smith Kline & French Labs, R&D, P.O. Box 1539, 19406-0939, King of Prussia</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Pharmaceutical Research</title><title level="j" type="sub">An Official Journal of the American Association of Pharmaceutical Scientists</title><title level="j" type="abbrev">Pharm Res</title><idno type="ISSN">0724-8741</idno><idno type="eISSN">1573-904X</idno><imprint><publisher>Kluwer Academic Publishers-Plenum Publishers</publisher><pubPlace>New York</pubPlace><date type="published" when="1989-01-01">1989-01-01</date><biblScope unit="volume">6</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="44">44</biblScope><biblScope unit="page" to="48">48</biblScope></imprint><idno type="ISSN">0724-8741</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0724-8741</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>amphoteric gel</term><term>gastric irritancy</term><term>gastric ulcer</term><term>indomethacin</term><term>oral bioavailability</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Indomethacin is a potent and efficacious antiinflammatory agent. However, a limiting side effect is its ability to cause gastric ulceration. This study was designed to investigate the effects of an amphoteric gel on the gastric ulcerogenicity and pharmacokinetics of indomethacin. Oral administration (5 mg/kg) in a suspension and a gel formulation were compared to an intravenous (iv) formulation of indomethacin in rats. The iv formulation administered to rats produced large severe ulcers in some rats but not in others. In contrast, the oral suspension produced small ulcers in all rats. The difference in toxicities is attributed to a centrally mediated action as a result of high plasma levels of indomethacin following iv administration, compared to locally mediated action with the suspension, resulting from local high concentrations of indomethacin on the apical epithelial surface because of the presence of indomethacin crystals. Oral administration of the gel formulation did not result in any gastric ulceration and improved the bioavailability of indomethacin to 115.5%, compared with 68.2% for the suspension. The reduced gastrointestinal toxicity of indomethacin in the gel was attributed to the gel's ability to dissolve indomethacin, preventing the localized high concentration observed with the suspension and possibly providing a gastric protectant phospholipid. The gel formulation doubled the oral bioavailability and the t max of indomethacin compared to the suspension but did not affect the half-life. The results indicate that the local irritant effect of indomethacin, in rats, can be reduced by appropriate formulation design and suggest that the ulcerogenicity index for indomethacin can be improved by the use of an amphoteric gel formulation.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Pennsylvanie</li></region></list><tree><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Liversidge, Gary G" sort="Liversidge, Gary G" uniqKey="Liversidge G" first="Gary G." last="Liversidge">Gary G. Liversidge</name></region><name sortKey="Dent, John" sort="Dent, John" uniqKey="Dent J" first="John" last="Dent">John Dent</name><name sortKey="Eickhoff, W Mark" sort="Eickhoff, W Mark" uniqKey="Eickhoff W" first="W. Mark" last="Eickhoff">W. Mark Eickhoff</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001490 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001490 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:17CAD7BA1E1699BF00CF1177D9CB10112F82CC38
|texte= Influence of Indomethacin Amphoteric Gel on Gastric Ulcerogenicity and Absorption of Indomethacin in Rats
}}
| This area was generated with Dilib version V0.6.33. |  |